Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series
- 22 August 2017
- journal article
- case report
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 76 (12), 2061-2064
- https://doi.org/10.1136/annrheumdis-2017-211560
Abstract
Background Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with numerous cancers. However, these therapies are associated with immune-related adverse events (irAEs), which are inflammatory side effects potentially affecting any organ. Cases of ICI-induced inflammatory arthritis have also been reported. In general, mild irAEs are treated with corticosteroids, while tumour necrosis factor-α (TNFα) inhibitors are reserved for refractory cases. However, prolonged use of TNFα inhibitor (TNFαi) can induce widespread, significant immunosuppression, which can negatively impact the antitumour efficacy of ICI therapy. Therefore, in clinical scenarios where patients develop severe immunotherapy-induced irAEs, an unmet need exists for alternative therapeutic strategies that are effective and without immune dampening effects. Case reports The anti-interleukin (IL)−6 receptor antibody, tocilizumab, is a biological agent Food and Drug Administration approved for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. Here, we report on three patients who developed severe polyarthritis while receiving ICI therapy and were treated with tocilizumab. All three patients demonstrated significant clinical improvement; one patient maintained a durable antitumour response derived from checkpoint inhibition. Conclusions These three cases suggest that anti-IL-6 receptor antibody may be an effective alternative to corticosteroids or TNFαi for the treatment of arthritis irAEs.Keywords
This publication has 20 references indexed in Scilit:
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterJournal of Clinical Oncology, 2015
- Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic MelanomaJournal of Immunotherapy, 2015
- Targeting Th17 cells in autoimmune diseasesTrends in Pharmacological Sciences, 2014
- IL-6 in Inflammation, Immunity, and DiseaseCold Spring Harbor Perspectives in Biology, 2014
- Cancer ImmunotherapyPublished by American Association for the Advancement of Science (AAAS) ,2013
- IL‐6: Regulator of Treg/Th17 balanceEuropean Journal of Immunology, 2010
- T Cells as Sources and Targets of TNF: Implications for Immunity and AutoimmunityCurrent directions in autoimmunity, 2010
- TNF-α is critical for antitumor but not antiviral T cell immunity in miceJCI Insight, 2007
- Interleukin-6 Gene Ablation in a Transgenic Mouse Model of Malignant Skin MelanomaThe American Journal of Pathology, 2005
- Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy?Melanoma Research, 1999